Trade Curis, Inc. - CRIS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.1448 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 3.0476 |
| Open | 3.1176 |
| 1-Year Change | -69.1% |
| Day's Range | 3.0276 - 3.1576 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 3.0276 | -0.0900 | -2.89% | 3.1176 | 3.1576 | 3.0276 |
| Feb 20, 2025 | 3.0476 | -0.1100 | -3.48% | 3.1576 | 3.2076 | 3.0476 |
| Feb 19, 2025 | 3.1476 | 0.0000 | 0.00% | 3.1476 | 3.1976 | 3.1176 |
| Feb 18, 2025 | 3.1076 | -0.0700 | -2.20% | 3.1776 | 3.3276 | 3.1076 |
| Feb 14, 2025 | 3.1576 | 0.1300 | 4.29% | 3.0276 | 3.2176 | 3.0276 |
| Feb 13, 2025 | 3.0876 | 0.0200 | 0.65% | 3.0676 | 3.1376 | 3.0276 |
| Feb 12, 2025 | 3.1076 | -0.0200 | -0.64% | 3.1276 | 3.1476 | 2.9976 |
| Feb 11, 2025 | 3.1176 | 0.0100 | 0.32% | 3.1076 | 3.1676 | 3.0676 |
| Feb 10, 2025 | 3.1276 | -0.0200 | -0.64% | 3.1476 | 3.1776 | 3.0876 |
| Feb 7, 2025 | 3.1276 | -0.1000 | -3.10% | 3.2276 | 3.2276 | 3.0876 |
| Feb 6, 2025 | 3.2876 | -0.0700 | -2.08% | 3.3576 | 3.4676 | 3.2676 |
| Feb 5, 2025 | 3.4276 | 0.0500 | 1.48% | 3.3776 | 3.5076 | 3.3776 |
| Feb 4, 2025 | 3.4076 | 0.0500 | 1.49% | 3.3576 | 3.4976 | 3.3476 |
| Feb 3, 2025 | 3.3276 | 0.0300 | 0.91% | 3.2976 | 3.4476 | 3.1976 |
| Jan 31, 2025 | 3.4376 | 0.1500 | 4.56% | 3.2876 | 3.4776 | 3.2576 |
| Jan 30, 2025 | 3.2376 | 0.0900 | 2.86% | 3.1476 | 3.2476 | 3.0876 |
| Jan 29, 2025 | 3.1676 | 0.0700 | 2.26% | 3.0976 | 3.2776 | 3.0676 |
| Jan 28, 2025 | 3.0576 | -0.0200 | -0.65% | 3.0776 | 3.1576 | 3.0376 |
| Jan 27, 2025 | 3.0776 | -0.3300 | -9.68% | 3.4076 | 3.4076 | 3.0076 |
| Jan 24, 2025 | 3.3576 | 0.0200 | 0.60% | 3.3376 | 3.5776 | 3.3376 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Curis, Inc. Company profile
About Curis, Inc.
Curis, Inc. is a biotechnology company focused on the development of therapeutics for the treatment of cancer. The Company’s drug candidates include CA-4948 and CI-8993. CA-4948 is an orally available small-molecule inhibitor of Interleukin-I receptor-associated kinase 4, which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas. It is also conducting a Phase I open-label, single-arm dose escalating trial in patients with acute myeloid leukemia, and myelodysplastic syndromes. CI-8993 is a monoclonal antibody designed to antagonize the V-domain Ig suppressor of the T cell activation signaling pathway. The Company initiated a Phase Ia/Ib trial of CI-8993 in patients with solid tumors. The Company’s products pipeline includes Fimepinostat, CA-170, CA-327, and PD1/TIM3 Program.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Curis, Inc. revenues decreased 2% to $10.6M. Net loss increased 52% to $45.4M. Revenues reflect Other revenue decrease of 100% to $1K. Higher net loss reflects Research & development Expenses B/F increase of 50% to $32M (expense), Other General and administrative, increase of 43% to $8M (expense), General and administrative expenses increase of 75% to $3.4M (expense).
Equity composition
Common Stock $.01 Par, 03/11, 125M auth., 77,397,663 issd., less 1,047,707 shs. in tres. @ $891K. Insiders own 2.72%. IPO 12/92, 3M shs. @ $7 by Montgomery Secs. *8/00, Co.merged with Ontogeny & Reprogenesis & chgd. name from Creative Biomolecules, Inc. FY'03&'04 are RES-Acct. Change. Summ. Qs reflects RES.
| Industry: | Biotechnology & Medical Research (NEC) |
128 Spring Street
4 Maguire Road
LEXINGTON
MASSACHUSETTS 02421
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com